Kestra Private Wealth Services LLC Decreases Stock Position in Illumina, Inc. $ILMN

Posted by Francis Steltz on Jul 5th, 2026

Kestra Private Wealth Services LLC trimmed its position in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 52.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,406 shares of the life sciences company’s stock after selling 3,801 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Illumina were worth $420,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Elyxium Wealth LLC bought a new position in Illumina during the fourth quarter valued at approximately $25,000. Board of the Pension Protection Fund bought a new stake in Illumina in the 4th quarter worth approximately $26,000. Creative Capital Management Investments LLC increased its stake in Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina during the 4th quarter worth approximately $26,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in shares of Illumina during the 4th quarter worth approximately $26,000. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $188.68 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The company has a market cap of $28.55 billion, a P/E ratio of 34.31, a PEG ratio of 3.53 and a beta of 1.47. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $189.46. The firm has a 50-day simple moving average of $154.74 and a two-hundred day simple moving average of $139.42.

Illumina (NASDAQ:ILMN – Get Free Report) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the firm posted $0.97 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts anticipate that Illumina, Inc. will post 5.21 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Barclays increased their price objective on shares of Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research report on Wednesday, June 24th. Evercore reiterated an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a research note on Thursday, May 14th. JPMorgan Chase & Co. upgraded Illumina from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $125.00 to $185.00 in a research report on Wednesday, June 10th. Finally, Piper Sandler raised their price objective on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Illumina presently has an average rating of “Hold” and a consensus target price of $148.94.

Read Our Latest Stock Report on Illumina

Insider Buying and Selling

In other news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the transaction, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. This represents a 4.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock worth $155,710,908 over the last ninety days. Corporate insiders own 2.90% of the company’s stock.

Illumina Company Profile

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.